IONIS PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Private, Subsidiary
- Established
- 1989-01-01
- Employees
- 927
- Market Cap
- -
- Website
- http://www.ionis.fr
GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
- Conditions
- Geographic AtrophyMacular Degeneration
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 332
- Registration Number
- NCT03815825
- Locations
- 🇪🇸
IONIS Investigative Site, Zaragoza, Spain
Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).
- Conditions
- hATTR AmyloidosisHealthy Volunteers
- Interventions
- First Posted Date
- 2018-11-02
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT03728634
- Locations
- 🇨🇦
Bio Pharma Services, Inc., Toronto, Ontario, Canada
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT03714776
- Locations
- 🇺🇸
Ohio Clinical Research - Lyndhurst, Lyndhurst, Ohio, United States
🇺🇸Orange County Research Center, Tustin, California, United States
🇺🇸Progressive Medical Research, Port Orange, Florida, United States
A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis
- Conditions
- Healthy SubjectsCystic Fibrosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT03647228
- Locations
- 🇩🇪
Universitätsmedizin Essen, Essen, Germany
🇩🇪Lungenheilkunde München-Pasing, München, Germany
🇬🇧Western General Hospital, Edinburgh, United Kingdom
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of IONIS FXI-LRx in up to 84 Healthy Volunteers
- Conditions
- Healthy Participants
- Interventions
- Drug: IONIS FXI-LRxDrug: Placebo
- First Posted Date
- 2018-07-11
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT03582462
- Locations
- 🇨🇦
BioPharma Services Inc., Toronto, Ontario, Canada
Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT03548415
- Locations
- 🇺🇸
University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States
🇺🇸St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
- Conditions
- Geographic AtrophyAge Related Macular Degeneration
- Interventions
- Drug: Placebo (sterline saline 0.9%)
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Registration Number
- NCT03446144
- Locations
- 🇦🇺
Sydney Retina Clinic Day Surgery, Sydney, New South Wales, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Lions Eye Institute, Nedlands, Western Australia, Australia
ATTR Expanded Access Program (EAP) by Ionis
- Conditions
- Amyloidosis, Hereditary
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2019-08-05
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Registration Number
- NCT03400098
A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 213
- Registration Number
- NCT03358030
- Locations
- 🇪🇸
Ionis Investigative Site, Alcalá De Henares, Madrid, Spain
Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT03334214
- Locations
- 🇬🇧
Ionis Investigational Site, Nottingham, United Kingdom